Cease and desist order issued against Fabunan drug

Share on facebook
Share on twitter
Share on email
Spread the love

The Food and Drug Administration (FDA) has issued a cease and desist order against the unregistered Fabunan antiviral injections which purported itself as a cure for the coronavirus disease 2019 (Covid-19), an official of the Department of Health (DOH) said Sunday.

“They still have not applied for CPR (certificate of product registration). They were already issued a cease and desist order by FDA, case buildup is being done already,” DOH Undersecretary Maria Rosario Vergeire relayed in a text message to reporters.

“We are studying the case already. FDA has jurisdiction when it comes to the unregistered drug or vaccine, and PRC (Professional Regulation Commission) for the practice of medicine,” she said.

To recall, on April 22, the palace enjoined the FDA to study the effectiveness of the Fabunan antiviral injection in curing patients with Covid-19 after viral posts about the drug circulated on social media.

The video post claimed that Fabunan is a patented antiviral drug against dengue developed by Washington-based Filipino doctor Ruben Fabunan. It also claimed that it is “proven to be used to treat Covid-19”.

The FDA adamantly warned the public that no drug and vaccine has been licensed “specifically for use in Covid-19 treatment” yet, so they are urged to be careful in believing such claims.

DOH, CHED sign MOU on hiring underboard nurses

Spread the love

Spread the loveMANILA — The Department of Health (DOH) and Commission on Higher Education (CHED) signed yesterday a memorandum of understanding (MOU) that

Viber: No info compromised in glitch

Spread the love

Spread the loveMANILA — Messaging platform Viber has assured its users that no information was compromised following a glitch in file transfers earlier

House strips Sara of confidential fund

Spread the love

Spread the loveMANILA — Vice President Sara Duterte and the Department of Education (DepEd) which she heads will not have confidential funds next